Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

November 8, 2022 4:01 PM EST

UDENYCA® net sales of $45.4 million in the third quarter 2022 CIMERLI launched in the United States on October 3rd Planning underway for 2023 commercial launches of toripalimab, YUSIMRY and UDENYCA® OBI Conference call today at 5 p.m. ET

REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights:

RECENT BUSINESS HIGHLIGHTS

CIMERLI (ranibizumab-eqrn), was approved in August 2022 by... More